热门资讯> 正文

周日报道，Longboard Pharmaceuticals报告了1b/2a期PacIFIC研究的中期结果，显示DEE患者癫痫发作减少了57.7%

2024-09-09 15:51

Bexicaserin achieved an overall median seizure reduction of 57.7% in countable motor seizures over an approximate 9-month treatment period
Favorable safety and tolerability results continue to be observed
Data to be presented at the 15th European Epilepsy Congress in Rome, Italy
Full 12-month OLE dataset expected early next year

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。